← Leaderboards
Rong Xu
Case Western Reserve University
$12,893,861
Attributed
$18,385,593
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,385,593 · 9
By mechanism
R01$10,107,542 · 5
DP2$2,377,500 · 1
RF1$2,342,002 · 1
T32$1,991,194 · 1
R56$1,567,355 · 1
Top collaborators
- Shu G Chen5 shared
- Pamela B Davis5 shared
- Thomas Louis Laframboise3 shared
- Vincent M Monnier3 shared
- Riqiang Yan1 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Arthur J McCullough$9,778,555
- Pamela B Davis$114,848,546
- Guo-Qiang Zhang$13,078,706
- David A. Zidar$1,694,866
- Shu G Chen$11,007,717
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposPharmaceutical PreparationsWeb AppPhenotypeGeneticKnowledge BaseInnovationSocialAnimal ModelS DiseaseUnited StatesOutputAffectS Disease ModelDementiaNeurodegenerative DisordersElectronic Health RecordTau ProteinsDiagnosisNeurodegenerative PhenotypeBaseMortalityGenesClinical Trials
Grant awards (28)
Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatments$772,838
R01 · FY2025 · AG · contact PI
Computational Genomic Epidemiology of Cancer (CoGEC) Training Program$290,787
T32 · FY2025 · CA · contact PI
Computational Genomic Epidemiology of Cancer (CoGEC) Training Program$227,204
T32 · FY2024 · CA · contact PI
Characterize multifaceted interactions between COVID-19 and alcohol use disorder based on real-time analysis of electronic health records of 62 million adult patients$362,250
R01 · FY2023 · AA · contact PI
Computational Genomic Epidemiology of Cancer (CoGEC) Training Program$299,414
T32 · FY2023 · CA · contact PI
Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatments$2,342,002
RF1 · FY2022 · AG · contact PI
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's Disease$708,999
R01 · FY2022 · AG · contact PI
Characterize multifaceted interactions between COVID-19 and alcohol use disorder based on real-time analysis of electronic health records of 62 million adult patients$362,250
R01 · FY2022 · AA · contact PI
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's Disease$708,999
R01 · FY2021 · AG · contact PI
Repositioning of Clinically Approved Drugs toward the Prevention and Risk Evaluation of Early Cataract Progression$658,609
R01 · FY2021 · EY
An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's Disease$607,564
R01 · FY2021 · AG · contact PI
Characterize multifaceted interactions between COVID-19 and alcohol use disorder based on real-time analysis of electronic health records of 62 million adult patients$362,250
R01 · FY2021 · AA · contact PI
Computational Genomic Epidemiology of Cancer (CoGEC) Training Program$302,251
T32 · FY2021 · CA · contact PI
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's Disease$729,794
R01 · FY2020 · AG · contact PI
Repositioning of Clinically Approved Drugs toward the Prevention and Risk Evaluation of Early Cataract Progression$678,627
R01 · FY2020 · EY
An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's Disease$607,249
R01 · FY2020 · AG · contact PI
Computational Genomic Epidemiology of Cancer (CoGEC) Training Program$312,738
T32 · FY2020 · CA · contact PI
Construct large-scale phenomes of disease and drugs and develop data-driven systems approaches to understand genetic links between Alzheimer's disease and Neuropsychiatric symptoms$777,445
R56 · FY2019 · AG · contact PI
Repositioning of Clinically Approved Drugs toward the Prevention and Risk Evaluation of Early Cataract Progression$679,562
R01 · FY2019 · EY
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's Disease$623,171
R01 · FY2019 · AG · contact PI
An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's Disease$534,336
R01 · FY2019 · AG · contact PI
Computational Genomic Epidemiology of Cancer (CoGEC) Training Program$278,063
T32 · FY2019 · CA · contact PI
Construct large-scale phenomes of disease and drugs and develop data-driven systems approaches to understand genetic links between Alzheimer's disease and Neuropsychiatric symptoms$789,910
R56 · FY2018 · AG · contact PI
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's Disease$635,171
R01 · FY2018 · AG · contact PI
An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's Disease$534,336
R01 · FY2018 · AG · contact PI
Computational Genomic Epidemiology of Cancer (CoGEC) Training Program$280,737
T32 · FY2018 · CA · contact PI
An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's Disease$541,537
R01 · FY2017 · AG · contact PI
Rapid reverse translational drug repositioning$2,377,500
DP2 · FY2014 · HD · contact PI